p53 is a major tumor suppressor in human cancer and the gene encoding p53 is mutated in about 50% of human cancers (Vogelstein et al., 2000) . p53 imparts its tumor suppressor function mainly by transcriptional regulation of its target genes, resulting in either growth arrest or apoptosis in a context-dependent manner (Vousden and Woude, 2000) . Post-translational modifications, especially phosphorylation has emerged as an important mechanism by which the protein stability of p53 is enhanced in response to numerous stimuli, including chemotherapeutic drugs (Ashcroft et al., 1999; Brooks and Gu, 2003) . Phosphorylation induces the DNA-binding activity of p53, which is a prerequisite for its trans-activation function. The antitumor drugs, doxorubicin (Dox) and cisplatin, have been widely used in the clinic for the treatment of a broad spectrum of cancers. It has been shown that Dox induces p53-dependent apoptosis in human tumor cells (Wang et al., 2004) and mouse fibroblasts (Dunkern et al., 2003) . In contrast, the p53-deficient colon cancer cells were sensitized to the effects of Dox as a result of the failure to induce the expression of the antiapoptotic cyclin-dependent kinase inhibitor p21 by p53 (Bunz et al., 1999) . Flavopiridol was used in phase 1 trial combined with cisplatin or carboplatin in patients with advanced malignancies (Bible et al., 2005) .
Recently, we had reported that ARC (4-amino-6-hydrazino-7-b-d-ribofuranosyl-7H-pyrrolo[2,3-d]-pyrimidine-5-carboxamide), a small molecule inhibitor of P-TEFb kinase (Cdk9/CyclinT1 complex) and a transcriptional inhibitor with anticancer properties, increased p53 levels although simultaneously repressing its target genes (Radhakrishnan and Gartel, 2006b ) similarly to the well-known anticancer drug flavopiridol (Demidenko and Blagosklonny, 2004) . We also found that p53 may be phosphorylated by P-TEFb and ARC inhibits phosphorylation of p53 by P-TEFb kinase in vitro (Radhakrishnan and Gartel, 2006a) . In the present study, we observed that ARC attenuated Dox-induced phosphorylation of p53 by multiple kinases (Figure 1a) , suggesting that ARC is a general kinase inhibitor. Moreover, ARC inhibited DNA-binding ability of p53 to its consensus sequence, as judged from gel-shift and supershift experiments with the nuclear extracts derived from HCT-116 colon cancer and MCF-7 breast cancer cells (Figure 1b ). In addition, ARC inhibited Doxinduced p53-dependent (Bunz et al., 1999) activation of p21 ( Figure 1c ). This is in contrast to actinomycin D, a widely used transcriptional inhibitor (but not a kinase inhibitor), which is known to enhance the DNA-binding ability of p53. ARC treatment alone did not show detectable DNA binding of p53, but treatment of cells with actinomycin D increased DNA binding-ability of p53 as expected (Figure 1d ). These data suggest that ARC inhibits Dox-induced DNA-binding activity of p53 due to its ability as a general kinase inhibitor but not as a transcriptional inhibitor.
To test how p53 phosphorylation may affect DNAbinding ability of p53, we performed in vitro kinase assays and gel-shift experiments with p53 and P-TEFb.
We found that p53 phosphorylated by P-TEFb, but not unphosphorylated p53, bound to DNA in a gel-shift assay (Figure 1e ), suggesting that phosphorylation of À1 ; Amersham Biosciences, Piscataway, NJ, USA) was added to a final concentration of 0.7 mCi ml À1 and incubated for a further 2 h. The cells were then harvested as described (Radhakrishnan et al., 2004) and the cell lysates were subjected to immunoprecipitation with anti-p53 antibody (PAb421; EMD Biosciences, San Diego, CA, USA), resolved on a SDS-PAGE and transferred on to a polyvinylidene fluoride membrane which was exposed to X-ray films. (b) HCT-116 and MCF-7 cells treated with ARC and Dox as indicated for 24 h were lysed in hypotonic buffer (10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid pH 7.9, 1.5 mM MgCl 2 , 10mM KCl, 0.2 mM phenylmethanesulpfonyl fluroide PMSF, 0.5 M dithiothreitol, 1 mM Na 3 VO 4 , 1 mM NaF, 1 mM Aprotinin and 1 mM Leupeptin) and the nuclei were pelleted and treated with highsalt buffer (20 mM HEPES pH 7.9, 20% (v/v) glycerol, 1.5 mM MgCl 2 , 0.5 M KCl, 0.2 mM ethylenediaminetetraacetic acid, 0.2 mM PMSF, 0.5 mM DTT, 1 mM Na 3 VO 4 , 1 mM NaF, 1 mM Aprotinin and 1 mM Leupeptin) to obtain the nuclear extracts. The nuclear extracts were used for the gel-shift reactions, which were set up as per the manufacturer's recommendations (E3050, Gel Shift Assay Core System, Promega, Madison, WI, USA). Briefly, 5 mg of nuclear extracts were incubated with 0.5 ng of double stranded p53 consensus oligonucleotides (sc-2579, Santa Cruz Biotechnology, Santa Cruz, CA, USA) that were labeled with g À32 P-ATP. The antip53 antibody PAb421 was used for supershifting the DNA-protein complexes. The reaction mixtures were resolved on a 4% acrylamide DNA-retardation gel, dried and exposed to X-ray film in the presence of intensifying screens. (c) HCT-116 colon cancer cells were treated with different combinations of Dox and ARC as indicated for 24 h and real-time quantitative RT-PCR was performed as described (Radhakrishnan et al., 2006) to determine the mRNA levels of p21. Briefly, RNA was extracted by the TRIzol method (Invitrogen) and cDNA was synthesized using the SuperScript First Strand Synthesis Kit according to the manufacturer's recommendations (Invitrogen). To amplify the cDNA, primers specific for p21 (sense, 5 0 -GCAGACCAGCATGACAGATTT-3 0 ; antisense, 5 0 -GGATTAGGGCTTCCTCTTGGA-3 0 ) or 18S rRNA (sense, 5 0 -GTCTGTGATGCCCTTAGATG-3 0 ; antisense, 5 0 -AGCTTATGACCCGCACTTAC-3 0 ) were used. These quantitative PCRs were run using the ABI 7900 HT system. The purity of the amplified products was ascertained by generating dissociation curves. Quantitation was carried out using a standard curve generated from the simultaneous amplification of the serial dilutions of the cDNA from untreated control cells. Mid-points of the log phase of the amplification curves as determined by the PCR machine were used for quantitation. (d) MCF-7 cells were treated with different combinations of Dox, actinomycin D (Act D) or ARC as indicated and nuclear extracts were used in gel-shift assay with labeled p53 consensus probe. Only the supershifted bands with the anti-p53 antibody PAb421 are shown. (e) p53 protein was used in gel-shift reactions with or without phosphorylation by P-TEFb as described (Radhakrishnan and Gartel, 2006a) . Briefly, purified human p53 protein (P2001-1, Protein One, Bethesda, MD, USA) was used as a substrate in the reactions either in the presence or in the absence of P-TEFb (a gift from Dr Sergei Nekhai), with the indicated concentrations of ARC. The kinase reactions were carried out at 301C for 30 min after which the samples were used for gel-shift assay with labeled p53 consensus probe. Only the supershifted bands with PAb421 are shown. p53 is both necessary and sufficient to induce DNAbinding ability of p53 in vitro. In addition, this experiment demonstrates that phosphorylation of p53 by P-TEFb is sufficient for its binding to DNA. Addition of ARC inhibited this process in a dosedependent manner (Figure 1e ), implying that this could partly be the mechanism by which the DNA-binding ability of p53 is attenuated in ARC-treated cells.
Next, we decided to test whether other P-TEFb inhibitors such as flavopiridol or DRB may inhibit Doxinduced binding of p53 to DNA. We found that while Dox induces strong binding of p53 to DNA, all P-TEFb inhibitors attenuate this binding (Figure 2a ). All PTEFb inhibitors decreased the amount of total and nuclear p53 after Dox treatment (Figure 2b ), but this decrease alone could not explain the dramatic reduction of p53 DNA binding (Figures 1b and 2a) caused by PTEFb inhibitors. Therefore, we propose that P-TEFb inhibitors decrease DNA binding of p53 and interfere with its activation by DNA-damaging agents by inhibiting its phosphorylation. The importance of phosphorylation of p53 with regard to its DNA-binding function remains contentious. It was initially assumed that phosphorylation of p53 stimulates its DNA-binding activity (Wang and Prives, 1995) . However, later using nutlin-3, a small molecule murine double minute antagonist (which induces p53 without phosphorylation on key serine residues), it was demonstrated that unphosphorylated p53 was equally competent in DNA binding when compared with phosphorylated p53 induced by Dox or etoposide (Thompson et al., 2004) . At the same time, it has also been suggested that phosphorylation of p53 by DNA-PK and Chk2 kinases are required for its DNA-binding ability after DNA damage was induced by ionizing radiation (Woo et al., 1998; Jack et al., 2004) . While Ser-15 on p53 was the target of phosphorylation by DNA-PK, it was not clear which residues are targeted by Chk2 to induce its DNAbinding ability (Jack et al., 2004) . Our results clearly indicate that phosphorylation of p53 is necessary for its DNA-binding activity.
It was shown before that Dox (Guillot et al., 1997) or P-TEFb inhibitor DRB (Gomes et al., 2006) alone could induce the accumulation of p53 and the activation of p21 transcription. We also observed that P-TEFb inhibitors individually may induce p21 (data not shown). However, our data paradoxically suggest that simultaneous treatment of cells with Dox and P-TEFb inhibitor ARC leads to the inhibition of phosphorylation of p53 (Figure 1a ), DNA binding of p53 ( Figure 1b) Figure 2 Attenuation of p53 DNA-binding activity by P-TEFb inhibitors is not due to reduction in the protein levels of p53. (a) Nuclear extracts from HCT-116 cells treated with the indicated concentrations of Dox, ARC, DRB or Flavo were subjected to gelshift assay with a radiolabeled p53 consensus probe as described in the legend to Figure 1 . The anti-p53 antibody PAb421 was used for supershifting the DNA-protein complexes. (b) Nuclear extracts from HCT-116 cells treated with the indicated concentrations of Doxorubicin (Dox), ARC, DRB or flavopiridol (Flavo) were harvested and nuclear extracts were prepared as described in the legend to Figure 1 . Also, total protein extracts from cells treated similarly were prepared as described before (Radhakrishnan et al., 2004) . Briefly, the cells were washed with phosphate-buffered saline and lysed in lysis buffer (20 mM HEPES, 1% Triton X-100, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 100 mM NaF, 10 mM Na 4 P 2 O 7 , 1 mM Na 3 VO 4 , 0.2 mM PMSF) supplemented with protease inhibitor tablet (Roche Applied Sciences). The nuclear and total extracts were resolved on a SDS-PAGE, transferred on to a PVDF membrane and subjected to immunoblotting with anti-p53 (sc-126 HRP, Santa Cruz Biotechnology), anti-Sp1 (sc-59, Santa Cruz Biotechnology) and anti-b-actin (A5441, Sigma) antibodies as indicated.
and to the suppression of p53-induced levels of p21 mRNA (Figure 1c ). Taken together, our results imply that the ability of ARC to inhibit the transcriptional activity of p53 protein could be attributed to its function as a general kinase inhibitor (via inhibition of phosphorylation of p53 by multiple kinases) rather than to its role as a transcriptional inhibitor (via inhibition of PTEFb phosphorylation of RNA Pol II and transcription elongation).
Our observation that P-TEFb inhibitors interfere with Dox-induced p53 phosphorylation and activation has important implications when a combination of these two classes of agents is being considered for anticancer therapy. If DNA-damaging agents induce cell death by p53-dependent mechanisms, then addition of P-TEFb inhibitors may compromise this effect. However, if a certain DNA-damaging agent is found to be more effective in p53-null cells (compared to cells with functional p53), then this agent can be used in combination with P-TEFb inhibitors (to antagonize p53 function) in tumors that harbor wild-type p53. Therefore, our results provide a key to rational selection of drug combinations in anticancer therapy.
